An alarming 39% of women and men develop cancer at some point in their lives, and the number one factor determining survival is the timing of the diagnosis. Catching cancer early, when it is most curable, means testing at-risk patients before they even have symptoms. CellSpring develops blood tests that can be used to screen at-risk patients and provide them with a cancer diagnosis at the absolute earliest stage, with unrivaled specificity and sensitivity.
Our patented technology allows us to exclusively identify novel biomarkers that are secreted into the blood by cancer cells. In collaboration with clinical partners who provide patient blood samples, we validate those biomarkers for their ability to diagnose and stage cancer.
